Where does Elisabet de los Pinos work?

Elisabet de los Pinos is Founder of Aura Biosciences.

What companies did Elisabet de los Pinos found?

Elisabet de los Pinos founded Aura Biosciences.

Where did Elisabet de los Pinos go to school?

Elisabet de los Pinos studied at MIT Sloan School of Management (Entrepreneurship Development Program); IE Business School (MBA, Management); The Institute of Cancer Research (Molecular Biology).

Elisabet de los Pinos

Founder

Founder at Aura Biosciences

Brookline, Massachusetts, United States

FoundedAura Biosciences

About

Elisabet de los Pinos is the founder and former CEO of Aura Biosciences (NASDAQ: AURA), a publicly traded, clinical-stage biotechnology company she developed in collaboration with Dr. John Schiller at the National Cancer Institute. She previously worked in the oncology business unit at Eli Lilly & Co., contributing to the European launch of the lung cancer drug Alimta, and held post-doctoral fellowships at the Institute of Cancer Research in London, the Mount Sinai School of Medicine, and the Georgetown School of Medicine. De los Pinos holds a Ph.D. in Molecular Biology from the University of Barcelona and an MBA from IE Business School, and she serves on the boards of Aura and the YPO Boston Chapter.

Founder at Aura Biosciences

Intro paths

→

In turn, Elisabet can intro founders to Aura Biosciences's investors below.

Aura Biosciences's investors · 11

Advent Life SciencesLondon Chiesi VenturesBoston · $5M checks Columbus Venture PartnersValencia Droia VenturesLeuven · $540K checks Foresite CapitalWest Hollywood Jazzya InvestmentsAlcobendas MedicxiLondon Myelin VCMontevideo · $250K – $1M checks OrbiMedNew York · $1M – $75M checks venBio PartnersSan Francisco Ysios CapitalBarcelona · $5.4M – $21.6M checks

Co-founders at Aura Biosciences

Elisabet de los Pinos, Ph.D.Executive Officer, Director

Experience

Aura BiosciencesFounder & CEOcurrent2010 — presentGreater Boston
Eli LillyBrand Manager Oncology Business Unit2003 — 2006Greater Madrid Metropolitan Area

Skills & more

Start-ups31Molecular Biology20Oncology42Biotechnology37Entrepreneurship15Drug Discovery15Pharmaceutics2Pharmaceutical Industry10Drug Development7Cancer5Lifesciences2Commercialization3

+8 more

Technology TransferGeneticsCell BiologyLicensingMergers & AcquisitionsLife SciencesBiopharmaceuticalsClinical Development

Languages Catalan · English · German · Spanish

Program on Negotiation — Harvard Law School
Global Leadership: Navigating the Future of Humanity — Harvard Kennedy School Executive Education

From Elisabet's professional profile.

Frequently asked questions

Who is Elisabet de los Pinos?: Elisabet de los Pinos is the founder and former CEO of Aura Biosciences (NASDAQ: AURA), a publicly traded, clinical-stage biotechnology company she developed in collaboration with Dr. John Schiller at the National Cancer Institute. She previously worked in the oncology business unit at Eli Lilly & Co., contributing to the European launch of the lung cancer drug Alimta, and held post-doctoral fellowships at the Institute of Cancer Research in London, the Mount Sinai School of Medicine, and the Georgetown School of Medicine. De los Pinos holds a Ph.D. in Molecular Biology from the University of Barcelona and an MBA from IE Business School, and she serves on the boards of Aura and the YPO Boston Chapter.
Where does Elisabet de los Pinos work?: Elisabet de los Pinos is Founder of Aura Biosciences.
What companies did Elisabet de los Pinos found?: Elisabet de los Pinos founded Aura Biosciences.
Where did Elisabet de los Pinos go to school?: Elisabet de los Pinos studied at MIT Sloan School of Management (Entrepreneurship Development Program); IE Business School (MBA, Management); The Institute of Cancer Research (Molecular Biology).

Same school

Also attended MIT Sloan School of Management518

Doug LeonePartner at Sequoia Capital; former Global Managing Partner Hemant TanejaCEO & Managing Director of General Catalyst Brad FeldCo-founder of Foundry and Techstars Chris MorrisProcess Specialist, Exit Readiness at Mayfair Equity Partners BirgitteInvestor at Investinor OlaInvestor at Investinor

+ 512 more

Also attended IE Business School203

Borja FernándezGeneral Partner at Inveready Technology Investment Group Gabriel FarmeInvestor at Graphene Ventures Hayata TokizawaVice President at Fin Capital Iñaki ArrolaInvestor at Kfund Carina SzpilkaInvestor at Kfund Caroline PhippsSenior Associate at True Beauty Ventures

+ 197 more

Also attended The Institute of Cancer Research1

Marc-Olivier TurgeonSenior Associate at Forbion

Also attended Icahn School of Medicine at Mount Sinai17

Justin RobenyAssociate at Osage University Partners Omar Njie, MDPrincipal at AlleyCorp Vinod MittaVenture Partner at Floating Point Tara BishopInvestor at Black Opal Ventures Scott GottliebPartner at New Enterprise Associates (NEA)Sharon HuangAssociate at Tau Ventures

+ 11 more

Shared employers

Also worked at Eli Lilly83

David MollerInvestor at Third Rock Ventures Jesper GromadaInvestor at Third Rock Ventures Mark LevinRetired Founding Partner at Third Rock Ventures Rhonda PachecoPresident, U.S. Business Unit and U.S. Country Head at Takeda Ventures Carlos PayaVenture Partner at Ysios Capital Kjersti FrognerInvestor at Almi Invest

+ 77 more